CTRI/2019/06/019838Other未知
A Prospective, Multicenter, Open-Label, Randomized Control Study to Compare the EfficacyAnd Tolerability Of A Synbiotic Formulation (Gutnext®) and Single Probiotic (Enterogermina®-Bacillus Clausii Spores), In The Management Of Pediatric Diarrhea
Dr Vijay Yewale0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- Other
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Infants and pediatric patients of either sex in the age group of 3 months to 15 years.
- •2.Patients with the diagnosis of acute diarrhea (greater than 4 semi watery stools day) as per
- •Type 6 of Bristol stool scale.31
- •3. Diarrheal symptoms for at least one day and lasting up to less then and equal to 7 days.
- •4. Patient willing to participate in the study and sign an informed consent form.
排除标准
- •1. Patients having chronic conditions (such as known chronic uncontrolled intestinal
- •disease such as coeliac disease cystic fibrosis food allergy immune deficiency inflammatory bowel disease gastrointestinal malformations abnormal gastrointestinal motility).
- •2. The presence of macroscopic blood in the faces.
- •3. Use of probiotic in the preceding 7 days.
- •4. Intractable vomiting (less than five successive times).
- •5. Known hypersensitivity to any of the ingredients of study medications.
研究者
相似试验
已完成
不适用
A Prospective, Multicenter, Open-Label, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-Abdominal Infections in Adults-A499 Bacterial infection, unspecifiedBacterial infection, unspecifiedA499PER-063-01MERCK SHARP & DOHME PERU S.R.L.,
已完成
不适用
Ertapenem versus Ceftriaxone and Metronidazole As Treatment For Complicated Intra-abdominal InfectionsComplicated intra-abdominal infectionsInfections and InfestationsOther and unspecified infectious diseasesISRCTN59616541Merck and Co., Inc. (USA)500
进行中（未招募）
1 期
A Study to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients with CLL and Coexisting Medical ConditionsCTIS2023-504034-22-00F. Hoffmann-La Roche AG397
进行中（未招募）
1 期
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine and Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) without DEL (17P) or TP53 mutatioChronic Lymphocytic Leukemia (CLL)MedDRA version: 21.0Level: LLTClassification code: 10008976Term: Chronic lymphocytic leukemia Class: 10029104CTIS2023-504036-17-00F. Hoffmann-La Roche AG166
招募中
2 期
Study of the effect of Siddha Treatment in addition to standard therapy in COVID-19 patientsCTRI/2020/06/025625Eminentlabs Business Solutions Pvt Ltd